Authors
Latest:
Biomarker Testing Standards-of-Care in Breast and Lung CancerThe panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.
Latest:
Future Perspectives in the Treatment of NeuroblastomaGiselle Sholler, MD, and Anurag Agrawal, MD, close their discussion with a look at the future of neuroblastoma treatment, highlighting research being done in areas such as immunotherapies, CAR T-cell therapy, and genomics for more targeted approaches aiming to enhance patient outcomes.
Latest:
Optimizing the Treatment of CLL With Novel TherapiesOncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.
Latest:
Dr. Funchain on the Rationale for the SWOG S1404 Trial in MelanomaPauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.
Latest:
Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid TumorsStéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.
Latest:
Dr Maxwell on Strategies to Optimize Genetic Testing in Metastatic Prostate CancerKara N. Maxwell, MD, PhD, discusses strategies to optimize the utility of genetic testing to better inform decision-making in prostate cancer treatment.
Latest:
Dr Roof on Disparities in Lung Cancer Mortality Rates in the United StatesLogan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.
Latest:
Dr. Jamieson on Treatment Considerations in MyelofibrosisCatriona Jamieson, MD, PhD, discusses treatment considerations for patients with myelofibrosis.
Latest:
Dr. Solomon on the Rationale For Liso-Cel in Relapsed/Refractory LBCLScott R. Solomon, MD, discusses the rationale for examining lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
Latest:
Dr Habermann on Ongoing Trials in MCL and MZLThomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.
Latest:
Leveraging Immunotherapy in GI Malignancies: Looking to the FutureIn this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
Latest:
Dr. Theurillat on Castration and AR Inhibition in Prostate CancerJean-Philippe Theurillat, MD, discusses castration and androgen receptor inhibition in prostate cancer.
Latest:
Dr Xu on Ongoing Biomarker Research in Metastatic RCCWenxin (Vincent) Xu, MD, discusses ongoing efforts to identify new biomarkers in metastatic renal cell carcinoma.
Latest:
Dr. Kim on the Synergistic Effect of PD-1H Blockade in AMLTae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..
Latest:
Dr Ball on Prior Research Supporting the SELECT-AML-1 Trial in Newly Diagnosed AMLBrian C. Ball, MD, discusses previous research on tamibarotene in newly diagnosed acute myeloid leukemia, and how these data support the ongoing phase 2 SELECT-AML-1 trial.
Latest:
Breast Cancer Treatment: Sequencing With Antibody-Drug ConjugatesClinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.
Latest:
Dr. Rose on the Importance of Genetic Testing in Ovarian CancerStephen L. Rose, MD, UW Health, discusses the importance of genetic testing in ovarian cancer.
Latest:
Dr. Concin on the Patient Population in the LIO-1 Trial in Advanced Gynecologic MalignanciesNicole Concin, MD, discusses the patient population that enrolled in the phase 1b/2 LIO-1 trial in advanced gynecologic malignancies.
Latest:
Endometrial Carcinoma: Clinical Case Scenario 3Oncologists debate the proper treatment of a patient with a grade 2 endometrial carcinoma tumor.
Latest:
Dr Noonan on Challenges Regarding the Sequencing and Selection of Therapies in HCCAnne M. Noonan, MBBCh, discusses unmet needs that remain to be addressed in hepatocellular carcinoma, including challenges regarding the navigation and sequencing of treatment options
Latest:
Dr. Seedor on Treatment Sequencing in Metastatic MelanomaRino S. Seedor, MD, discusses findings from the phase 3 DREAMseq trial, which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.
Latest:
Dr. Tseng on the Goal of the TARPSWG Analysis in Retroperitoneal SarcomaWilliam W. Tseng, MD, discusses the goals of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.
Latest:
Dr. Jain on Efficacy With Maintenance Avelumab Plus BSC in Metastatic Urothelial CancerRohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.
Latest:
Dr. Devitt on Utilizing PD-L1 in Biomarker-Guided Therapies in Bladder CancerMichael Devitt, MD, discusses utilizing PD-L1 status in biomarker-guided therapies for patients with bladder cancer.
Latest:
Breast Nerve Preservation and Grafting: How Surgeons Can Help Mitigate Sensation LossMore surgeons are having in-depth conversations with their patients with breast cancer and prophylactic patients about the fact that nerves will have to be cut during their mastectomy, how that will impact sensation and quality of life, and how surgeon collaboration and breast neurotization can help restore sensation.
Latest:
Dr. Bordoni on the Utility of Adjuvant Atezolizumab in the Adjuvant Setting in NSCLCRodolfo Bordoni, MD, discusses the utility of atezolizumab in the adjuvant setting in non–small cell lung cancer.
Latest:
Dr. Schenk on the Effect of Nivolumab Plus Relatlimab in Basal Cell CarcinomaKara M. Schenk, MD, discusses the effect of nivolumab plus relatlimab in advanced basal cell carcinoma.
Latest:
Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid SyndromeDrs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.
